In the Trp-Kyn pathway, the rate-limiting enzyme, indoleamine 2,3-dioxygenase 1 (IDO1), diminishes insulin resistance by reducing inflammation, suggesting that tryptophan metabolism reduces the complications of T2DM [45]. The gene discussed is IDO1; the disease is Insulin resistance.